Cargando…

Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC

INTRODUCTION: Hyperprogressive disease (HPD) as a consequence of immune checkpoint inhibitors in NSCLC has been reported in multiple studies. However, inconsistent results in incidence and survival outcomes within studies, together with different assessment methods, have led to increasing controvers...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocha, Pedro, Ramal, Didac, Ripoll, Enric, Moliner, Laura, Corbera, Alex, Hardy-Werbin, Max, Orrillo, Mayra, Taus, Álvaro, Zuccarino, Flavio, Gibert, Joan, Perera-Bel, Júlia, Casadevall, David, Arriola, Edurne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474364/
https://www.ncbi.nlm.nih.gov/pubmed/34589976
http://dx.doi.org/10.1016/j.jtocrr.2020.100115
_version_ 1784575198666686464
author Rocha, Pedro
Ramal, Didac
Ripoll, Enric
Moliner, Laura
Corbera, Alex
Hardy-Werbin, Max
Orrillo, Mayra
Taus, Álvaro
Zuccarino, Flavio
Gibert, Joan
Perera-Bel, Júlia
Casadevall, David
Arriola, Edurne
author_facet Rocha, Pedro
Ramal, Didac
Ripoll, Enric
Moliner, Laura
Corbera, Alex
Hardy-Werbin, Max
Orrillo, Mayra
Taus, Álvaro
Zuccarino, Flavio
Gibert, Joan
Perera-Bel, Júlia
Casadevall, David
Arriola, Edurne
author_sort Rocha, Pedro
collection PubMed
description INTRODUCTION: Hyperprogressive disease (HPD) as a consequence of immune checkpoint inhibitors in NSCLC has been reported in multiple studies. However, inconsistent results in incidence and survival outcomes within studies, together with different assessment methods, have led to increasing controversy regarding the concept of HPD. METHODS: Consecutive patients treated with nivolumab (N = 42) or docetaxel (N = 37) were evaluated. HPD was quantified by applying three different methods (tumor growth rate [TGR], tumor growth kinetics [TGK], and Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]). HPD rates were compared between and within both cohorts using the different methods. RESULTS: Using TGR, TGK, and RECIST 1.1, we identified seven (16.7%), seven (16.7%), and six (14.3%) patients with HPD in the nivolumab cohort and three (8.1%), four (10.8%), and five (13.6%) in the docetaxel cohort, respectively. We observed a higher concordance between TGR and TGK (90.1%) compared with RECIST 1.1 (31.3% and 37.5% with TGR and TGK, respectively). We found no significant differences in the overall survival between patients with progressive disease and HPD in either cohort. CONCLUSIONS: TGR and TGK revealed high concordance rates for identifying patients with HPD in NSCLC. The incidence of HPD was numerically higher in patients treated with immune checkpoint inhibitors. Standardization of methods for measuring HPD and its exploration in larger studies are needed to establish its clinical meaning in NSCLC.
format Online
Article
Text
id pubmed-8474364
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84743642021-09-28 Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC Rocha, Pedro Ramal, Didac Ripoll, Enric Moliner, Laura Corbera, Alex Hardy-Werbin, Max Orrillo, Mayra Taus, Álvaro Zuccarino, Flavio Gibert, Joan Perera-Bel, Júlia Casadevall, David Arriola, Edurne JTO Clin Res Rep Brief Report INTRODUCTION: Hyperprogressive disease (HPD) as a consequence of immune checkpoint inhibitors in NSCLC has been reported in multiple studies. However, inconsistent results in incidence and survival outcomes within studies, together with different assessment methods, have led to increasing controversy regarding the concept of HPD. METHODS: Consecutive patients treated with nivolumab (N = 42) or docetaxel (N = 37) were evaluated. HPD was quantified by applying three different methods (tumor growth rate [TGR], tumor growth kinetics [TGK], and Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]). HPD rates were compared between and within both cohorts using the different methods. RESULTS: Using TGR, TGK, and RECIST 1.1, we identified seven (16.7%), seven (16.7%), and six (14.3%) patients with HPD in the nivolumab cohort and three (8.1%), four (10.8%), and five (13.6%) in the docetaxel cohort, respectively. We observed a higher concordance between TGR and TGK (90.1%) compared with RECIST 1.1 (31.3% and 37.5% with TGR and TGK, respectively). We found no significant differences in the overall survival between patients with progressive disease and HPD in either cohort. CONCLUSIONS: TGR and TGK revealed high concordance rates for identifying patients with HPD in NSCLC. The incidence of HPD was numerically higher in patients treated with immune checkpoint inhibitors. Standardization of methods for measuring HPD and its exploration in larger studies are needed to establish its clinical meaning in NSCLC. Elsevier 2020-10-28 /pmc/articles/PMC8474364/ /pubmed/34589976 http://dx.doi.org/10.1016/j.jtocrr.2020.100115 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Brief Report
Rocha, Pedro
Ramal, Didac
Ripoll, Enric
Moliner, Laura
Corbera, Alex
Hardy-Werbin, Max
Orrillo, Mayra
Taus, Álvaro
Zuccarino, Flavio
Gibert, Joan
Perera-Bel, Júlia
Casadevall, David
Arriola, Edurne
Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC
title Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC
title_full Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC
title_fullStr Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC
title_full_unstemmed Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC
title_short Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC
title_sort comparison of different methods for defining hyperprogressive disease in nsclc
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474364/
https://www.ncbi.nlm.nih.gov/pubmed/34589976
http://dx.doi.org/10.1016/j.jtocrr.2020.100115
work_keys_str_mv AT rochapedro comparisonofdifferentmethodsfordefininghyperprogressivediseaseinnsclc
AT ramaldidac comparisonofdifferentmethodsfordefininghyperprogressivediseaseinnsclc
AT ripollenric comparisonofdifferentmethodsfordefininghyperprogressivediseaseinnsclc
AT molinerlaura comparisonofdifferentmethodsfordefininghyperprogressivediseaseinnsclc
AT corberaalex comparisonofdifferentmethodsfordefininghyperprogressivediseaseinnsclc
AT hardywerbinmax comparisonofdifferentmethodsfordefininghyperprogressivediseaseinnsclc
AT orrillomayra comparisonofdifferentmethodsfordefininghyperprogressivediseaseinnsclc
AT tausalvaro comparisonofdifferentmethodsfordefininghyperprogressivediseaseinnsclc
AT zuccarinoflavio comparisonofdifferentmethodsfordefininghyperprogressivediseaseinnsclc
AT gibertjoan comparisonofdifferentmethodsfordefininghyperprogressivediseaseinnsclc
AT pererabeljulia comparisonofdifferentmethodsfordefininghyperprogressivediseaseinnsclc
AT casadevalldavid comparisonofdifferentmethodsfordefininghyperprogressivediseaseinnsclc
AT arriolaedurne comparisonofdifferentmethodsfordefininghyperprogressivediseaseinnsclc